Shore Capital Reaffirms “Buy” Rating for Genus (LON:GNS)

Genus (LON:GNS)‘s stock had its “buy” rating restated by Shore Capital in a report released on Wednesday, Marketbeat reports.

Genus Trading Up 4.3 %

LON GNS opened at GBX 1,921.54 ($25.53) on Wednesday. The stock has a market cap of £1.26 billion, a P/E ratio of 159.28, a price-to-earnings-growth ratio of 2.87 and a beta of 0.37. Genus has a fifty-two week low of GBX 1,424 ($18.92) and a fifty-two week high of GBX 2,155 ($28.63). The stock has a 50 day simple moving average of GBX 1,790.46 and a two-hundred day simple moving average of GBX 1,775.42. The company has a debt-to-equity ratio of 53.12, a quick ratio of 1.08 and a current ratio of 1.80.

Genus (LON:GNS) last announced its quarterly earnings results on Thursday, February 27th. The company reported GBX 39.80 ($0.53) EPS for the quarter. Genus had a return on equity of 1.41% and a net margin of 1.18%. On average, analysts forecast that Genus will post 70.9644323 earnings per share for the current year.

Insider Activity

In other news, insider Jorgen Kokke sold 19,967 shares of Genus stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of GBX 1,731 ($23.00), for a total transaction of £345,628.77 ($459,185.29). 0.75% of the stock is currently owned by company insiders.

Genus Company Profile

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.